Document is current
Any future updates will be listed below
-
Authors
Thomas, Geethu Emily
Voisin, Veronique
Nouri, Kazem
Hurren, Rose
Fang, Karen Kai-Lin
Chegini, Ali https://orcid.org/0009-0007-8249-7258
Gronda, Marcela
Yan, Yongran https://orcid.org/0009-0005-7337-4331
MacLean, Neil
Jitkova, Yulia
Ling, Dakai
Ma, Mary
Wang, Xiao Ming
Arruda, Andrea
Spadavecchio, Vito
Minden, Mark D.
Zhang, Li
Lee, Jong Bok
Schimmer, Aaron D. https://orcid.org/0000-0003-4023-3899
-
Funding
Funding for this research was provided by:
Gouvernement du Canada | Canadian Institutes of Health Research (FDN-154282)
- License Information
-
More Information
Article History
Received: 5 May 2025
Accepted: 7 May 2026
First Online: 30 May 2026
Competing interests
: The authors declare the following competing interests: A.D.S. has received research funding from Takeda Pharmaceuticals, BMS and Medivir AB, and consulting fees/honorarium from Takeda, Astra-Zeneca, BMS, and Novartis, Pharmaceuticals. A.D.S. is named on a patent application for the use of DNT cells to treat AML. A.D.S. is on the medical and scientific board of the Leukemia and Lymphoma Society of Canada. LZ has financial interests (e.g., holdings/shares) in WYZE Biotech Co Ltd and previously received research funding and consulting fee/honorarium from the company. LZ and JBL are inventors of DNT cell technology-related patents and intellectual properties for the treatment of AML. Vito Spadavecchio has controlling interest in Interlinked Therapeutics. The remaining authors declare no competing interests.
